Introduction
Apple’s (AAPL) Services division is now the second-largest business segment in the company’s arsenal. A big driver of this growth has been Apple Music. However, nearly one and a half years later, the question still remains, “What impact is Apple Music going to have?”
Over the past year, the company has seen its iPhone, Mac and “Other Products” segments drop by double digits in revenue. During the same time frame, Apple Music has grown 22% in revenue alongside Apple Services 24% growth. It has been a small saving grace for investors during the most recent earnings release.
How much does it cost to service each subscriber?
Royalties
According to the New York Times, Apple pays $0.002 per stream in royalty fees. Additionally, music publishers earn $0.47 per 1000 streams. This totals $2.47 per 1,000 streams, which can be treated as its cost of goods sold.
In 2013, Spotify’s (Private:MUSIC) users listened to approximately 110 minutes of streamed music per day. Assuming the average song length is three minutes, there would be 1,100 songs listened to per month. That would be the equivalent of $2.72 worth of Apple Music payments.
Top 5 Safest Stocks To Own Right Now: NVIDIA Corporation(NVDA)
Advisors’ Opinion:
- [By WWW.THESTREET.COM]
And you thought out-sized gains were only relegated to Apple (AAPL) , Tesla (TSLA) , Nvidia (NVDA) and Amazon (AMZN) .
Why not try biotech stocks on for size.
- [By Kumar Abhishek]
Another tailwind for AMD are its Vega GPUs. The Sunnyvale, California, based chipmaker is scheduled to preview its Vega GPUs today in itsCapsaicin & Creamevent at Gamer’s Developers Congress (GDC) in California.The latest reports about Vega GPUs suggest this could be the fastest GPU that AMD has ever built and could give NVIDIA’s(NASDAQ:NVDA)Titan GPU a run for its money.The chipmaker had unveiled its latest GPU line-up at the CES 2017 event in January, and preliminary benchmarks revealed that AMD’s new flagship outperformed Nvidia’s GTX 1080by 15-20% in terms of raw performance. Vega could help the chipmaker gain some market share in the mid and high-end GPU segments. AMD has already been gaining market share in the GPU market. In Q4, AMD’s market share increased to 14.4% from 13% in the previous quarter.Vega GPUs will help AMD capture a bigger chunk of the PC/gaming market where the company’s performance was not great in the previous quarter.
- [By Virendra Singh Chauhan]
The CPU and GPU business have come together at the same time for AMD. The recently released Ryzen CPUs and Radeon Instinct GPUs have been the best out of the AMD stable, in as far back as memory goes. The focus on machine learning could also provide AMD with new revenue streams from the data center (CPU as well as GPU) as well as the autonomous driving markets. These markets have, so far, been ruled by Nvidia (for GPUs) and Intel (for CPUs). Intel (NSDQ:INTC) has seen its data center group report nearly 7% YoY growth in FY 2016, with Q316 revenue registering a10% YoY jump. On the GPGPU side, NVIDIA (NSDQ:NVDA) has seen its data center revenue accelerate by 121% YoY through the first 3 quarters of FY 2017 (ending in Jan 2017) while seeing its autonomous car revenue climbing by 58% YoY. In comparison, AMDs ‘Enterprise, embedded and semi-custom segment’ which includes revenue from server processors (AMDs limited exposure to the data center market), is up by 5.95% YoY (first 3 quarters of 2016).
- [By Sreekanth Anasa]
AMD Radeon RX 500 Series Vega GPU will be previewed at the company’sCapsaicin & Cream event, part of the GDC 2017 on Feb 28th. With its latest 14nm graphics architecture Vega,AMD has made the most incremental step forward in the last 5 years in terms of architecture tweaking. The latest leaks and reports about Vega GPUs suggest this could be the fastest GPU that the chipmaker has ever built and would give NVIDIA’s(NASDAQ:NVDA) GTX 1080 GPU a run for its money. AMD had disclosed a host of new details about the Polaris graphics architecture RX 400 series (unreleased then)during its last yearCapsaicin event in March, a similar thing about Vega GPUs cannot be rolled out. With Vega GPU leaks already suggesting impressive results, the latest Vega sneak-peek could potentially drive AMD stock much higher.
- [By Virendra Singh Chauhan]
AMD as well as NVIDIA have been on a tear through 2016. Advanced Micro Devices, Inc. (NSDQ:AMD) stock is up nearly 210% YTD. NVIDIA Corporation (NSDQ:NVDA) stock isn’t far behind, having gained over 185% YTD. Having netted these strong 3-figure gains, investors are obviously happy with how the semiconductors story has unfolded in 2016. However, with the year now drawing to a close, which of these two would be a better semiconductor play, going forward? This would be an obvious question that many investors might have in their mind.
Top 5 Safest Stocks To Own Right Now: Amgen Inc.(AMGN)
Advisors’ Opinion:
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) is expected to report its most recent quarterly results on Wednesday. The consensus estimates call for $3.00 in EPS and $5.61 billion in revenue. Shares closed trading at $160.41 on Friday, in a 52-week range of $133.64 to $184.21. The consensus price target is $185.13.
- [By Ben Levisohn]
After years of rising and falling in tandem, the biotech sector is all about stock picking now. Credit Suisse analyst Alethia Young and team, for instance, upgraded Regeneron Pharmaceuticals (REGN), and added Celgene (CELG) to its Focus List today. But Amgen (AMGN) wasn’t so lucky as Young cut it to Neutral from Outperform. She explains why:
- [By Keith Speights]
Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY), and Amgen (NASDAQ:AMGN) stand out as three of the most likely suitors for Incyte. Here’s why these big drugmakers could be interested in making a significant acquisition.
- [By Ben Levisohn]
Amgen (AMGN) has tumbled 3.6% to $158.65 after beating earnings forecasts but missing on sales.
Buffalo Wild Wings (BWLD) has dropped 3% to $157.51 after its earnings fell short of the Street consensus.
- [By Johanna Bennett]
Shares of Amgen (AMGN) led the drop in the S&P 500 today falling almost 6.4% to close at $168.61 after the drug maker unveiledlong-awaited data on its anti-cholesterol drug Repatha.
Can shares of Amgen rebound from todays selloff?
Yes, is the answer from RBC Capital Management analyst Michael Yee. He argues that the drug makers share price can grind back up if access to Repatha increases over the next few quarters. Earlier today, Amgen released data from an outcome study that missed expectations, leading some analyst to predict that health plans will continue to restrict access to the drug.
As Yee writes:
A number of key developments midday at the ACC conference that should shed increased confidence that Repatha reimbursement and utilization will continue to increase over time driving a new growth driver for AMGN and increased confidence in a new product cycle. If reimbursement does start to open up over next few quarters (tracking IMS scripts and other datapoints) and AMGN manages their execution on quarters/guidance – stock should recover off today’s overreaction reflecting high expectations
- [By Maxx Chatsko]
Shares of Radius Health (NASDAQ:RDUS) rose over 20% Monday morning after Amgen (NASDAQ:AMGN) announced worrisome complications were discovered during a phase 3 trial for its osteoporosis drug candidate, Evenity. While the drug candidate met its primary endpoint in a more than 4,000-patient phase 3 study, a high rate of serious heart-related side effects were discovered. The drug was previously expected to gain marketing approval from the U.S. Food and Drug Administration in July, but that decision will now be delayed by up to a year or more, if the drug is approved at all.
Top 5 Safest Stocks To Own Right Now: MINDBODY, Inc.(MB)
Advisors’ Opinion:
- [By Joe Tenebruso]
Mindbody (NASDAQ:MB) provides cloud-based software solutions to the health and wellness industry: Think spas, yoga studios, and fitness classes. It’s a massive market that’s gone largely underserved — and Mindbody is working to address that need.
- [By Peter Graham]
Small cap online wellness services stock MINDBODY Inc (NASDAQ: MB) reportedQ2 2017 earnings after the market closed Wednesday with results beating expectations. Total revenue was up 31% to $44.1 million as subscription and services revenue rose 29% to $26.0 million and payments revenue rose 37% to $17.6 million. End of period subscribers increased 6% year over year to 59,345, end of period High Value Subscribers increased 13% year over year, average monthly revenue per subscriber (ARPS) grew 21% year over year to approximately $244 and payments volume increased 22% year over year to over $1.9 billion. The GAAP net losswas $4.4 million versus a GAAP net loss of $6.6 million. Rick Stollmeyer, Co-founder and CEO of MINDBODY, commented:
- [By Peter Graham]
The Q3 2016 earnings report for small cap online wellness services stock MINDBODY Inc (NASDAQ: MB) is scheduled for after the market closes onWednesday (October 26th). MINDBODY Inc along withmid cap fitnessdevice stockFitbit Inc (NYSE: FIT) and small cap fitness center operator Planet Fitness Inc (NYSE: PLNT)allhad IPOsin the summer of 2015 raisingtalk of a fitness stock bubble brewing.
- [By Peter Graham]
A long term performance chart shows Fitbit Inc initially surging after its IPO before loosing most of its value while large capGarmin Ltd (NASDAQ: GRMN) (which hasa fitness segment)has moved back and forth from positive to negative territory and small cap online wellness services stockMINDBODY Inc (NASDAQ: MB) has taken off for the past year:
- [By Peter Graham]
A long term performance chart shows Fitbit initially surging after its IPO before loosing most of its value while large capGarmin Ltd (NASDAQ: GRMN) (which hasa fitness segment)has been range bound for over a year and small cap online wellness services stockMINDBODY Inc (NASDAQ: MB) has taken off with performance starting to moderate:
Top 5 Safest Stocks To Own Right Now: Cleveland BioLabs, Inc.(CBLI)
Advisors’ Opinion:
- [By Lisa Levin]
In trading on Tuesday, healthcare shares fell by 0.98 percent. Meanwhile, top losers in the sector included Cleveland BioLabs, Inc. (NASDAQ: CBLI), down 25 percent, and Infinity Pharmaceuticals Inc. (NASDAQ: INFI), down 8 percent.
- [By Alex McGuire]
As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…
Pharmaceutical Stock Current Share Price April 2017 Gain
Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6%
Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7%
Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2%
Axovant Sciences Ltd. (NYSE: AXON) $24.43 +62.3%
Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) $5.49 +46.7%
Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) $8.67 +44.9%
Akebia Therapeutics Inc. (Nasdaq: AKBA) $13.07 +43.3%
Akorn Inc. (Nasdaq: AKRX) $33.28 +38.9%
Rockwell Medical Inc. (Nasdaq: RMTI) $8.78 +37.4%
Akari Therapeutics Plc. (Nasdaq ADR: AKTX) $15.02 +35.4%
The best-performing pharma stock of the month – Cleveland BioLabs Inc. – surged 120.6% to $3.53 a share by April 28. That crushed both the Nasdaq Biotech Index’s 1.5% gain and the Dow Jones’ 1.3% rise over the same period.
- [By Alex McGuire]
You see, penny stocks are attractive because they can offer double-digit or even triple-digit returns in a very short time. For example, Cleveland BioLabs Inc. (Nasdaq: CBLI) skyrocketed from $1.56 at the Thursday, April 13, close to $5.10 on Wednesday, April 19. That’s a stunning 227% return in just three sessions (the markets were closed that Friday).
Top 5 Safest Stocks To Own Right Now: GigaMedia Limited(GIGM)
Advisors’ Opinion:
- [By Jim Robertson]
Today, our Under the Radar Moversnewsletter suggested small cap online gaming and cloud computing GigaMedia Limited (NASDAQ: GIGM) as a bullish long trade:
